drugset / Trial / NCT00690950

A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

NCT00690950

Phase 4 Unknown 50 enrolled Urologic Consultants of Southeastern PA
RandomizedSingle-groupOpen-labelTreatment

Summary

Hypothesis: Dutasteride will perform better than finasteride in decreasing prostate volume, improving symptoms based on International Prostate Symptom score,and lower pvr based on the scientific information that dutasteride inhibits both Type I and II 5-alpha-reducatase vs. finasteride which only inhibits the Type II enzyme

Timeline

Start
2008-05
Primary completion
2009-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dutasteride Small molecule 0.5 mg